Jewish publication may drop Coulter over ‘F-ing Jews’ tweet

Coulter defended her ” f—ing Jews” tweet saying “It’s not about Jewish people; it’s about Republican panderers.”

By JTA
September 21, 2015 13:46
1 minute read.
Ann Coulter

Ann Coulter. (photo credit: REUTERS)

A conservative Jewish publication may drop conservative political pundit Ann Coulter’s column in the wake of her tweet slamming Republican candidates for pandering to “f—ing Jews.”

The founder of the online Jewish World Review, Binyamin Jolkovsky, told the Daily Beast that he has reached out to Coulter but that she had not responded as of Friday.

Her latest column, which appeared on the website on Sept. 17, a day after the CNN Republican debate and her infamous tweet and follow-up tweets, included an editor’s note reading: “This column was prepared before the author’s anti-Semitic rant. JWR reached out to her and awaits her reply.”

Her column has been appearing on the website since 2000.

“She could have been drunk, she could have been high, I don’t know, I have to give her the benefit of the doubt … but I don’t have to delude myself,” Jolkovsky told The Daily Beast. “Pandering to Jewish money is about as anti-Semitic a stereotype as you could put forth. Her ‘eff-ing Jews’ comment is not identifying Israel — it’s identifying Jews, plural, and all Jews. There is no excuse for that. You can’t just wiggle out of something that vile and hateful.”

Jolkovsky said it was the first time that Coulter has not emailed him back in a timely manner. He said he has not yet decided whether to pull her column, but that many readers would like to see that happen.

Coulter defended her ” f—ing Jews” tweet saying “It’s not about Jewish people; it’s about Republican panderers.”

She later called her comments “pro-Semitic. Where is all the GOP pandering on Israel getting us? US becoming Mexico very bad for Israel. ”


Related Content

A building belonging to generic drug producer Teva, Israel's largest company with a market value of
October 20, 2019
Opioid settlement talks fail with Teva, landmark trial expected Monday

By REUTERS

Cookie Settings